Weekly Investment Analysts’ Ratings Updates for Intellia Therapeutics (NTLA)

A number of firms have modified their ratings and price targets on shares of Intellia Therapeutics (NASDAQ: NTLA) recently:

• 4/28/2026 – Intellia Therapeutics had its price target raised by The Goldman Sachs Group, Inc. from $8.00 to $9.00. They now have a “sell” rating on the stock.
• 4/28/2026 – Intellia Therapeutics had its “outperform” rating reaffirmed by Citigroup Inc..
• 4/28/2026 – Intellia Therapeutics had its price target raised by Canaccord Genuity Group Inc. from $48.00 to $58.00. They now have a “buy” rating on the stock.
• 4/28/2026 – Intellia Therapeutics had its price target raised by Citizens Jmp from $28.00 to $30.00. They now have a “market outperform” rating on the stock.
• 4/27/2026 – Intellia Therapeutics was given a new $35.00 price target by Leerink Partners.
• 4/27/2026 – Intellia Therapeutics had its price target raised by Morgan Stanley from $11.00 to $15.00. They now have an “equal weight” rating on the stock.
• 4/27/2026 – Intellia Therapeutics had its price target raised by Robert W. Baird from $7.00 to $13.00. They now have a “neutral” rating on the stock.
• 4/27/2026 – Intellia Therapeutics had its price target raised by Chardan Capital from $27.00 to $30.00. They now have a “buy” rating on the stock.
• 4/21/2026 – Intellia Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 3/25/2026 – Intellia Therapeutics was upgraded by Truist Financial Corporation to “strong-buy”.
• 3/7/2026 – Intellia Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/4/2026 – Intellia Therapeutics was upgraded by JonesTrading from “hold” to “buy”. They now have a $29.00 price target on the stock.
• 3/3/2026 –
• 3/3/2026 – Intellia Therapeutics had its price target lowered by Canaccord Genuity Group Inc. from $54.00 to $48.00. They now have a “buy” rating on the stock.
• 3/3/2026 – Intellia Therapeutics had its price target raised by Leerink Partners from $27.00 to $29.00. They now have an “outperform” rating on the stock.
• 3/3/2026 – Intellia Therapeutics had its price target raised by Royal Bank Of Canada from $9.00 to $15.00. They now have a “sector perform” rating on the stock.
• 3/3/2026 – Intellia Therapeutics had its price target raised by Wells Fargo & Company from $12.00 to $15.00. They now have an “equal weight” rating on the stock.
• 3/3/2026 – Intellia Therapeutics had its price target raised by HC Wainwright from $25.00 to $30.00. They now have a “buy” rating on the stock.
• 3/3/2026 – Intellia Therapeutics had its price target raised by Citizens Jmp from $21.00 to $28.00. They now have a “market outperform” rating on the stock.
• 3/2/2026 – Intellia Therapeutics had its “neutral” rating reaffirmed by Bank of America Corporation.
• 3/2/2026 – Intellia Therapeutics was upgraded by William Blair from “market perform” to “outperform”.

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical?stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease?causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.